南京威尔药业集团股份有限公司 2020 年半年度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2020 年半年度报告 二〇二〇年八月 中国 南京 1 / 122 南京威尔药业集团股份有限公司 2020 年半年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 □适用 √不适用 2 / 122 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人吴仁荣、主管会计工作负责人唐群松及会计机构负责人（会计主管人员）杨轶声 明：保证半年度报告中财务报告的真实、准确、完整。 | 第一节 | 释义 4 | | --- | --- | | 第二节 | 公司简介和主要财务指标 ...

南京威尔药业集团股份有限公司 2020 年第一季度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业集团股份有限公司 2020 年第一季度报告 二〇二〇年四月 中国 南京 1 / 24 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 7 | 南京威尔药业集团股份有限公司 2020 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | -736,169.83 | | 3 / 24 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 1,481,408,055.91 1,458,270,541.59 1.59 归属于上市公司股东 的净资产 1,273,648,462.36 1,241,215,205.79 2.61 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营 ...

Financial Performance - In 2019, Nanjing Well Pharmaceutical achieved a revenue of RMB 880.76 million, representing a 9.90% increase compared to RMB 801.45 million in 2018[22]. - The net profit attributable to shareholders of the listed company for 2019 was RMB 128.11 million, up 14.57% from RMB 111.81 million in 2018[22]. - The net cash flow from operating activities increased by 103.42% to RMB 129.69 million in 2019, compared to RMB 63.76 million in 2018[23]. - As of the end of 2019, the total assets of the company reached RMB 1.46 billion, an increase of 80.43% from RMB 808.20 million at the end of 2018[23]. - The company's net assets attributable to shareholders increased by 101.95% to RMB 1.24 billion at the end of 2019, compared to RMB 614.61 million at the end of 2018[23]. - Basic earnings per share decreased by 13.13% to CNY 1.39 compared to CNY 1.60 in the previous year[24]. - The weighted average return on equity decreased by 8.6 percentage points to 11.15% from 19.75% in the previous year[24]. - The operating profit for the year was CNY 157.16 million, reflecting a growth of 23.13% year-on-year[41]. - The company reported a total revenue of CNY 220,030,417.15 in Q4, showing a slight decline from Q3's CNY 222,941,080.13[26]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 4.5 per 10 shares (including tax) and to increase capital by 4 shares for every 10 shares held[6]. - The cumulative undistributed profits as of December 31, 2019, amounted to RMB 239.71 million[6]. - In 2019, the cash dividend amounted to 42 million RMB, representing 32.78% of the net profit attributable to ordinary shareholders[120]. - The proposed profit distribution plan includes a cash dividend of 4.5 RMB per 10 shares (before tax) and a capital reserve increase of 4 shares for every 10 shares held[119]. Research and Development - The company invested CNY 32.91 million in R&D, accounting for 3.74% of total operating revenue, with 27 projects under development[44]. - The company emphasizes independent research and development, with a focus on injectable pharmaceutical excipients, and collaborates with universities and research institutions[70]. - The company has established a provincial-level technology center and a provincial-level engineering research center for water-soluble pharmaceutical excipients to enhance its R&D capabilities[70]. - The company has several key R&D projects, including the development of mixed polyols and polysorbate 80, with respective investments of RMB 119.28 million and RMB 280.34 million[75]. - The average R&D investment among comparable companies in the industry was RMB 1,228.68 million, while the company significantly exceeded this average[75]. Market and Product Development - The company focuses on the research, production, and sales of pharmaceutical excipients and synthetic lubricating base oils, leveraging core technologies in ether polymerization and ester synthesis[33]. - The pharmaceutical excipient industry is expected to grow significantly due to stricter regulations and increasing quality demands from pharmaceutical manufacturers[37]. - Sales revenue from synthetic lubricating base oils grew by 9.01%, maintaining the company's leading position in the domestic market[41]. - Sales revenue from pharmaceutical excipients increased by 12.59%, supported by a focus on major clients and market segments[42]. - The company plans to enhance its product development in pharmaceutical excipients, particularly for injectable excipients, to meet the increasing demand in China's pharmaceutical formulation industry[107]. Financial Stability and Risks - The asset-liability ratio decreased from 23.95% at the beginning of the period to 14.88% at the end of the period, indicating improved financial stability[185]. - The company faces risks related to product and technology development, including the potential for R&D failures and stringent regulatory requirements impacting its operational performance[115]. - The company is exposed to risks from fluctuations in the supply and prices of key raw materials, such as ethylene oxide and propylene oxide, which could affect production capacity[115]. - Environmental protection regulations are becoming stricter, potentially increasing operational costs if the company fails to meet higher standards[116]. Shareholder and Management Commitments - The company has established a cash dividend policy to strengthen the protection of minority investors' rights[119]. - The controlling shareholders and actual controllers commit to fulfilling all public commitments made during the IPO process[147]. - The company will not guarantee future profits, and investors are advised not to base investment decisions solely on the measures announced[144]. - Major shareholders have committed to not reducing their holdings below the issuance price within two years after the lock-up period[139]. Environmental Compliance - The company reported no exceedance of pollutant discharge limits during the reporting period, with all major pollutants within approved ranges[172]. - The company has implemented online monitoring devices at pollutant discharge points, ensuring compliance with environmental regulations[175]. - The company has established an emergency response plan for environmental incidents, which has been filed with local environmental authorities[174]. Corporate Governance - The company has a stock price stabilization plan that will be activated if the stock price falls below the audited net asset value per share for 20 consecutive trading days within 3 years post-listing[131]. - The management's commitment to shareholding regulations will remain in effect regardless of any changes in their positions within the company[128]. - The company will report any changes in shareholdings by senior management to ensure transparency and compliance with regulatory requirements[127].

南京威尔药业股份有限公司 2019 年第三季度报告 公司代码：603351 公司简称：威尔药业 南京威尔药业股份有限公司 2019 年第三季度报告 二〇一九年十月 中国 南京 1 / 27 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 7 | | 四、 | 附录 8 | 南京威尔药业股份有限公司 2019 年第三季度报告 一、 重要提示 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | | 上年度末 | | 本报告期末比上年度末 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 增减(%) | | | | 总资产 | 1,455,038,160.29 | | 808,198,479.88 | | 80.03% | | | | 归属于上市公司股 | 1,223,483,240.18 | | 614,609,988.51 | | | | 99.07% | | 东的净资产 | | | | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2019 was ¥437,784,553.22, representing a 7.44% increase compared to ¥407,453,253.43 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥76,504,853.39, a 25.10% increase from ¥61,153,446.56 in the previous year[19]. - The net cash flow from operating activities increased by 38.96% to ¥56,645,131.24, up from ¥40,764,378.95 in the same period last year[21]. - The operating profit for the same period was 90.55 million yuan, reflecting a growth of 26.03% compared to the previous year[33]. - The total comprehensive income for the first half of 2019 was approximately ¥78.1 million, compared to ¥63.0 million in the same period of 2018, representing an increase of about 24.5%[136]. Assets and Liabilities - Total assets increased by 70.75% to ¥1,379,992,819.21, up from ¥808,198,479.88 at the end of the previous year[19]. - The company's cash and cash equivalents increased significantly by 520.26% to ¥250,816,266.68, primarily due to funds raised from issuing shares[39]. - The total current assets of the company reported as RMB 824,817,641.78 as of June 30, 2019, compared to RMB 318,251,885.35 at the end of December 2018, indicating a significant increase of approximately 158%[123]. - Total liabilities decreased to CNY 190,380,610.60 from CNY 193,588,491.37, a decline of about 1.1%[125]. Shareholder Information - The company raised a net amount of 538.50 million yuan from its stock issuance on the Shanghai Stock Exchange, providing sufficient funding for its investment projects[30]. - The controlling shareholders have committed to not transferring their shares for 36 months post-listing, ensuring stability in shareholding[55]. - The company will ensure that any stock reduction by major shareholders complies with relevant laws and regulations[73]. - Shareholders holding more than 5% of shares commit to not reducing their holdings by more than 25% of their total shares within two years after the lock-up period[72]. Research and Development - The company launched 14 new R&D projects in the first half of 2019, including 12 related to pharmaceutical excipients and 2 for advanced synthetic lubricating base oils[35]. - Research and development expenses rose by 8.8% to RMB 13,860,175.23, reflecting the company's commitment to innovation[37]. - The company emphasizes the importance of internal control systems to enhance operational efficiency and reduce financial risks[79]. Market and Competition - The company is actively pursuing international market expansion, particularly in the EU and the US, to achieve global sales of pharmaceutical excipients[34]. - The competition in the pharmaceutical excipients market is intensifying, with international giants entering the market, potentially affecting the company's market share[48]. - The company faces risks related to the uncertainty in the standardization process of the pharmaceutical excipients industry, which may impact future development[46]. Environmental and Safety Compliance - The company has established a comprehensive safety production management system and has not experienced any major safety or environmental incidents during the reporting period[36]. - The company has implemented environmental protection measures, with all major pollutants discharged within approved limits during the reporting period[95]. - The company has signed and filed an emergency response plan for environmental incidents with local environmental authorities[99]. Financial Management and Commitments - The company commits to strict cost and expense control to improve profitability and operational efficiency[79]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders if it cannot meet its obligations due to non-force majeure reasons[80]. - Compensation will be provided to investors for direct losses incurred due to the company's failure to fulfill commitments[80]. Accounting and Financial Reporting - The company follows the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect its financial status accurately[162]. - The company's accounting period runs from January 1 to December 31 each year[163]. - The company has not reported any significant accounting errors or changes in accounting policies during the reporting period[95].

公司代码：603351 公司简称：威尔药业 南京威尔药业股份有限公司 2019 年第一季度报告 二〇一九年四月 南京威尔药业股份有限公司 2019 年第一季度报告 中国 南京 1 / 19 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 7 | 南京威尔药业股份有限公司 2019 年第一季度报告 一、 重要提示 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末 | | | --- | --- | --- | --- | --- | | | | | 增减(%) | | | 总资产 | 1,386,181,300.51 | 808,198,479.88 | | 71.51 | | 归属于上市公司 | 1,191,274,062.47 | 614,609,988.51 | | 93.83 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) ...

Financial Performance - In 2018, the company achieved a revenue of RMB 801.45 million, representing a 15.46% increase compared to RMB 694.11 million in 2017[21] - The net profit attributable to shareholders was RMB 111.81 million, a 4.08% increase from RMB 107.43 million in the previous year[21] - The company's total assets reached RMB 808.20 million at the end of 2018, up 11.40% from RMB 725.52 million in 2017[22] - The net cash flow from operating activities was RMB 63.76 million, a decrease of 10.54% compared to RMB 71.27 million in 2017[22] - Basic earnings per share for 2018 were CNY 2.24, an increase of 4.19% compared to CNY 2.15 in 2017[23] - The weighted average return on equity decreased to 19.75% in 2018 from 22.21% in 2017, a decline of 2.46 percentage points[23] - Total revenue for the fourth quarter of 2018 was CNY 201,543,172.08, with a net profit attributable to shareholders of CNY 27,712,793.89[25] - The company reported a net cash flow from operating activities of CNY 5,818,920.64 in the fourth quarter of 2018[26] - Non-recurring gains and losses totaled CNY 9,881,807.91 in 2018, compared to CNY 4,502,865.63 in 2017[27] - The operating cost increased by 22.26% to RMB 552,142,027.33, impacting overall profitability[49] - The gross profit margin decreased by 4.21 percentage points to 31.12%[51] Research and Development - The company conducted 21 independent R&D projects in 2018, with 16 related to pharmaceutical excipients and 5 to advanced synthetic lubricating base oils[44] - A total of 15 pharmaceutical excipient products completed registration with the National Medical Products Administration in 2018[44] - The company holds 22 authorized patents, including 17 invention patents, emphasizing its commitment to R&D and innovation[38] - The company maintained a high level of R&D investment to ensure technological leadership and core competitiveness[38] - The company focuses on R&D in drug excipients, particularly for injectable formulations, maintaining a leading technological advantage in the industry[86] - The company’s R&D investment for the reporting period amounted to 24.70 million RMB, representing 3.08% of operating revenue and 4.02% of net assets[88] - The company is focusing on R&D projects that align with market demand and leverage its strengths to maintain a competitive edge[91] Market and Sales Strategy - The company focuses on the research, production, and sales of pharmaceutical excipients and synthetic lubricant base oils, with core technologies in ether polymerization and ester synthesis[30] - The sales model is direct to market, primarily targeting pharmaceutical manufacturers and large lubricant producers[32] - The revenue from pharmaceutical excipients was RMB 205,700,739.36, with a slight increase of 0.66% year-on-year[51] - Total sales revenue from the top five customers reached CNY 301.66 million, accounting for 37.64% of the annual total sales[56] - Total procurement from the top five suppliers was CNY 221.58 million, representing 50.14% of the annual total procurement[56] Risk Management - The company highlighted risks including safety and environmental risks, as well as market operational risks[7] - The company is exposed to risks related to the supply and price volatility of key raw materials, such as ethylene oxide and propylene oxide, which are critical for production[111] - The company faces operational risks due to the need for continuous improvement in quality control systems to meet increasing regulatory demands and production scale[110] - The company is at risk of losing market share if it fails to maintain advantages in product structure, quality, technology, and research and development amid increasing competition[108] - The company faces risks related to the uncertain standardization process in the pharmaceutical excipients industry, which may impact future development[106] Corporate Governance and Compliance - The company has committed to fulfilling all public commitments made during the IPO process, with measures in place for accountability in case of non-compliance[145] - The controlling shareholders have pledged to adhere to all public commitments made during the IPO process, with specific measures for accountability in case of non-compliance[146] - The company has made commitments to avoid conflicts of interest and ensure fair competition during the reporting period[118] - The company will comply with all relevant laws and regulations regarding shareholding and transfer restrictions[120] - The company has not faced any penalties from securities regulatory agencies in the past three years[194] Environmental Responsibility - The company has implemented online monitoring devices for pollutant discharge points, ensuring compliance with environmental regulations[169] - The company has established emergency response plans for environmental incidents and has filed them with local environmental authorities[168] - The company has maintained normal operation of its pollution control facilities, including a wastewater treatment plant with a capacity of 125 tons per day[166] - The company has not reported any instances of exceeding pollutant discharge limits during the reporting period[165] - The company has prepared environmental impact reports for all construction projects, which have been approved by local environmental departments[167] Shareholder Relations and Dividends - The company plans to distribute a cash dividend of RMB 6 per 10 shares and to increase capital by 4 shares for every 10 shares held[5] - The accumulated undistributed profits as of December 31, 2018, amounted to RMB 162.22 million[5] - The company distributed cash dividends of 40,000,020 RMB in 2018, representing 35.77% of the net profit attributable to ordinary shareholders[117] - In 2017, the cash dividends amounted to 30,000,000 RMB, accounting for 27.92% of the net profit attributable to ordinary shareholders[117] - The cash dividends for 2016 were 18,000,000 RMB, which was 21.17% of the net profit attributable to ordinary shareholders[117] Employee and Management Structure - The company has a total of 508 employees including subsidiaries[195] - The company has established a comprehensive salary management system to motivate employees and ensure sustainable development[196] - In 2018, the company emphasized talent development through a training plan aimed at enhancing employee skills and management capabilities[197] - The company has implemented a governance structure that includes a board of directors, supervisory board, and various specialized committees[199] Capital and Financing - The company successfully raised RMB 538,497,400 through the issuance of 16,666,700 shares, enhancing its capital base[47] - The company’s IPO application was approved by the CSRC on August 21, 2018, marking a significant milestone in its capital market strategy[46] - The company will not increase salaries or allowances for directors and senior management until all negative impacts from non-fulfillment of commitments are eliminated[145] Future Outlook and Strategic Plans - The company plans to enhance its product series in pharmaceutical excipients, focusing on high-value, competitive products for special formulations such as sustained release and targeted delivery[102] - The market expansion strategy includes increasing market share in pharmaceutical excipients and synthetic lubricants, aiming for global sales through quality certifications in Europe and the US[103] - The company aims to strengthen its R&D capabilities by leveraging local government funding and partnerships with academic institutions to enhance innovation[104] - The company will continue to invest in research and development to quickly convert technological achievements into production capacity, enhancing profitability and risk resistance[141]